Tarsus Pharmaceuticals (TARS)

• Market cap: $1.61B
• 1 day: -7.55%
• 5 days: -16.77%
• 1 month: -18.17%
• 3 months: -12.87%
• 6 months: 52.43%
• Year to date: -23.66%
• 1 year: 26.96%
• 5 years: 104.57%
• 10 years: 104.57%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Employees: 244

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

141% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 22

54% more capital invested

Capital invested by funds: $1.44B [Q3] → $2.22B (+$778M) [Q4]

17% more funds holding

Funds holding: 162 [Q3] → 190 (+28) [Q4]

14% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 56

0% more funds holding in top 10

Funds holding in top 10: 8 [Q3] → 8 (+0) [Q4]

10.42% less ownership

Funds ownership: 115.35% [Q3] → 104.93% (-10.42%) [Q4]

74% less call options, than puts

Call options by funds: $4.57M | Put options by funds: $17.5M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $62 47% upside
• Avg. target: $67 59% upside
• High target: $72 71% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Barclays Balaji Prasad 38% 1-year accuracy 16 / 42 met price target	47% upside $62	Overweight Maintained	27 Jan 2025
Oppenheimer Francois Brisebois 46% 1-year accuracy 17 / 37 met price target	71% upside $72	Outperform Maintained	22 Jan 2025